143 related articles for article (PubMed ID: 28569061)
1. Structure-Based Design of Scaffolds Targeting PDE10A by INPHARMA-NMR.
Codutti L; Grimaldi M; Carlomagno T
J Chem Inf Model; 2017 Jun; 57(6):1488-1498. PubMed ID: 28569061
[TBL] [Abstract][Full Text] [Related]
2. The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening.
Fan HT; Guo JF; Zhang YX; Gu YX; Ning ZQ; Qiao YJ; Wang X
Mol Med Rep; 2018 Jan; 17(1):388-393. PubMed ID: 29115449
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
[TBL] [Abstract][Full Text] [Related]
4. Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects.
García AM; Brea J; González-García A; Pérez C; Cadavid MI; Loza MI; Martinez A; Gil C
Molecules; 2017 Sep; 22(9):. PubMed ID: 28869560
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
[TBL] [Abstract][Full Text] [Related]
6. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
Vlasceanu A; Jessing M; Kilburn JP
Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors.
Chino A; Seo R; Amano Y; Namatame I; Hamaguchi W; Honbou K; Mihara T; Yamazaki M; Tomishima M; Masuda N
Chem Pharm Bull (Tokyo); 2018; 66(3):286-294. PubMed ID: 29491261
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
Meegalla SK; Huang H; Illig CR; Parks DJ; Chen J; Lee YK; Wilson KJ; Patel SK; Cheung WS; Lu T; Kirchner T; Askari HB; Geisler J; Patch RJ; Gibbs AC; Rady B; Connelly M; Player MR
Bioorg Med Chem Lett; 2016 Sep; 26(17):4216-22. PubMed ID: 27491708
[TBL] [Abstract][Full Text] [Related]
9. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
Matthiesen K; Nielsen J
Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
[TBL] [Abstract][Full Text] [Related]
10. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
[TBL] [Abstract][Full Text] [Related]
11. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
Amin HS; Parikh PK; Ghate MD
Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
[TBL] [Abstract][Full Text] [Related]
13. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP.
Handa N; Mizohata E; Kishishita S; Toyama M; Morita S; Uchikubo-Kamo T; Akasaka R; Omori K; Kotera J; Terada T; Shirouzu M; Yokoyama S
J Biol Chem; 2008 Jul; 283(28):19657-64. PubMed ID: 18477562
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism.
Schwan G; Barbar Asskar G; Höfgen N; Kubicova L; Funke U; Egerland U; Zahn M; Nieber K; Scheunemann M; Sträter N; Brust P; Briel D
ChemMedChem; 2014 Jul; 9(7):1476-87. PubMed ID: 24729456
[TBL] [Abstract][Full Text] [Related]
16. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
Kehler J; Nielsen J
Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
[TBL] [Abstract][Full Text] [Related]
17. PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Jansen C; Kooistra AJ; Kanev GK; Leurs R; de Esch IJ; de Graaf C
J Med Chem; 2016 Aug; 59(15):7029-65. PubMed ID: 26908025
[TBL] [Abstract][Full Text] [Related]
18. Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDE's).
Moraca F; Negri A; de Oliveira C; Abel R
J Chem Inf Model; 2019 Jun; 59(6):2729-2740. PubMed ID: 31144815
[TBL] [Abstract][Full Text] [Related]
19. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
